schliessen

Filtern

 

Bibliotheken

Role of temozolomide after radiotherapy for newly diagnosed diffuse brainstem glioma in children: results of a multiinstitutional study (SJHG-98).

BACKGROUNDThe role of chemotherapy in the treatment of children with newly diagnosed diffuse brainstem glioma is uncertain. In the current study, the authors tested the efficacy of temozolomide treatment after radiotherapy (RT) in this setting. METHODSPatients ages 3-21 years were eligible for the c... Full description

Journal Title: Cancer January 1, 2005, Vol.103(1), pp.133-139
Main Author: Broniscer, Alberto
Other Authors: Iacono, Lisa , Chintagumpala, Murali , Fouladi, Maryam , Wallace, Dana , Bowers, Daniel C , Stewart, Clinton , Krasin, Matthew J , Gajjar, Amar
Format: Electronic Article Electronic Article
Language: English
Subjects:
ID: ISSN: 0008-543X
Link: http://search.proquest.com/docview/67344570/?pq-origsite=primo
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: proquest67344570
title: Role of temozolomide after radiotherapy for newly diagnosed diffuse brainstem glioma in children: results of a multiinstitutional study (SJHG-98).
format: Article
creator:
  • Broniscer, Alberto
  • Iacono, Lisa
  • Chintagumpala, Murali
  • Fouladi, Maryam
  • Wallace, Dana
  • Bowers, Daniel C
  • Stewart, Clinton
  • Krasin, Matthew J
  • Gajjar, Amar
subjects:
  • Administration, Oral–Adverse Effects
  • Adolescent–Pharmacokinetics
  • Antineoplastic Agents, Alkylating–Therapeutic Use
  • Brain Stem Neoplasms–Drug Therapy
  • Camptothecin–Pathology
  • Child–Radiotherapy
  • Child, Preschool–Administration & Dosage
  • Dacarbazine–Analogs & Derivatives
  • Female–Adverse Effects
  • Glioma–Analogs & Derivatives
  • Humans–Pharmacokinetics
  • Infusions, Intravenous–Therapeutic Use
  • Male–Drug Therapy
  • Treatment Outcome–Pathology
  • Treatment Outcome–Radiotherapy
  • Abridged
  • Antineoplastic Agents, Alkylating
  • Irinotecan
  • Dacarbazine
  • Camptothecin
  • Temozolomide
ispartof: Cancer, January 1, 2005, Vol.103(1), pp.133-139
description: BACKGROUNDThe role of chemotherapy in the treatment of children with newly diagnosed diffuse brainstem glioma is uncertain. In the current study, the authors tested the efficacy of temozolomide treatment after radiotherapy (RT) in this setting. METHODSPatients ages 3-21 years were eligible for the current multiinstitutional study. An optional window therapy regimen consisting of 2 cycles of intravenous irinotecan (10 doses of 20 mg/m2 per day separated by 2 days of rest per cycle) was delivered over 6 weeks and was followed by conventionally fractionated RT. The 5-day schedule of temozolomide (200 mg/m2 per day) was initiated 4 weeks after RT and was continued for a total of 6 cycles. The pharmacokinetics of temozolomide and its active metabolite, 5-(3-methyltriazen-1-yl)imidazole-4-carboxamide (MTIC), were analyzed during Cycles 1 and 3. RESULTSThirty-three patients (median age at diagnosis, 6.4 years) were enrolled. Of the 16 patients who received window therapy, 6 had irinotecan treatment discontinued due to clinical progression (n=5) or toxicity (n=1); the remaining 10 experienced disease stabilization after 2 cycles. All patients completed RT (median dose, 55.8 gray). Twenty-nine patients received a combined total of 125 cycles of temozolomide. Grade 3/4 neutropenia and thrombocytopenia occurred in 33% and 29% of all temozolomide cycles, respectively. In approximately one-third of the cycles, dose reduction was required due to myelosuppression. No correlation was demonstrated between temozolomide/MTIC exposure and myelosuppression at the conclusion of Cycle 1. All patients died of disease progression (median survival, 12 months). The estimated 1-year survival rate was 48% (standard error, 8%). CONCLUSIONSThe administration of temozolomide after RT did not alter the poor prognosis associated with newly diagnosed diffuse brainstem glioma in children.
language: eng
source:
identifier: ISSN: 0008-543X
fulltext: fulltext
issn:
  • 0008543X
  • 0008-543X
url: Link


@attributes
ID904949726
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordid67344570
sourceidproquest
recordidTN_proquest67344570
sourcesystemOther
pqid67344570
galeid155719630
display
typearticle
titleRole of temozolomide after radiotherapy for newly diagnosed diffuse brainstem glioma in children: results of a multiinstitutional study (SJHG-98).
creatorBroniscer, Alberto ; Iacono, Lisa ; Chintagumpala, Murali ; Fouladi, Maryam ; Wallace, Dana ; Bowers, Daniel C ; Stewart, Clinton ; Krasin, Matthew J ; Gajjar, Amar
contributorBroniscer, Alberto (correspondence author) ; Broniscer, Alberto (record owner)
ispartofCancer, January 1, 2005, Vol.103(1), pp.133-139
identifierISSN: 0008-543X
subjectAdministration, Oral–Adverse Effects ; Adolescent–Pharmacokinetics ; Antineoplastic Agents, Alkylating–Therapeutic Use ; Brain Stem Neoplasms–Drug Therapy ; Camptothecin–Pathology ; Child–Radiotherapy ; Child, Preschool–Administration & Dosage ; Dacarbazine–Analogs & Derivatives ; Female–Adverse Effects ; Glioma–Analogs & Derivatives ; Humans–Pharmacokinetics ; Infusions, Intravenous–Therapeutic Use ; Male–Drug Therapy ; Treatment Outcome–Pathology ; Treatment Outcome–Radiotherapy ; Abridged ; Antineoplastic Agents, Alkylating ; Irinotecan ; Dacarbazine ; Camptothecin ; Temozolomide
descriptionBACKGROUNDThe role of chemotherapy in the treatment of children with newly diagnosed diffuse brainstem glioma is uncertain. In the current study, the authors tested the efficacy of temozolomide treatment after radiotherapy (RT) in this setting. METHODSPatients ages 3-21 years were eligible for the current multiinstitutional study. An optional window therapy regimen consisting of 2 cycles of intravenous irinotecan (10 doses of 20 mg/m2 per day separated by 2 days of rest per cycle) was delivered over 6 weeks and was followed by conventionally fractionated RT. The 5-day schedule of temozolomide (200 mg/m2 per day) was initiated 4 weeks after RT and was continued for a total of 6 cycles. The pharmacokinetics of temozolomide and its active metabolite, 5-(3-methyltriazen-1-yl)imidazole-4-carboxamide (MTIC), were analyzed during Cycles 1 and 3. RESULTSThirty-three patients (median age at diagnosis, 6.4 years) were enrolled. Of the 16 patients who received window therapy, 6 had irinotecan treatment discontinued due to clinical progression (n=5) or toxicity (n=1); the remaining 10 experienced disease stabilization after 2 cycles. All patients completed RT (median dose, 55.8 gray). Twenty-nine patients received a combined total of 125 cycles of temozolomide. Grade 3/4 neutropenia and thrombocytopenia occurred in 33% and 29% of all temozolomide cycles, respectively. In approximately one-third of the cycles, dose reduction was required due to myelosuppression. No correlation was demonstrated between temozolomide/MTIC exposure and myelosuppression at the conclusion of Cycle 1. All patients died of disease progression (median survival, 12 months). The estimated 1-year survival rate was 48% (standard error, 8%). CONCLUSIONSThe administration of temozolomide after RT did not alter the poor prognosis associated with newly diagnosed diffuse brainstem glioma in children.
languageeng
source
version6
lds50peer_reviewed
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
backlink$$Uhttp://search.proquest.com/docview/67344570/?pq-origsite=primo$$EView_record_in_ProQuest_(subscribers_only)
search
creatorcontrib
0Broniscer, Alberto
1Iacono, Lisa
2Chintagumpala, Murali
3Fouladi, Maryam
4Wallace, Dana
5Bowers, Daniel C
6Stewart, Clinton
7Krasin, Matthew J
8Gajjar, Amar
titleRole of temozolomide after radiotherapy for newly diagnosed diffuse brainstem glioma in children: results of a multiinstitutional study (SJHG-98).
descriptionBACKGROUNDThe role of chemotherapy in the treatment of children with newly diagnosed diffuse brainstem glioma is uncertain. In the current study, the authors tested the efficacy of temozolomide treatment after radiotherapy (RT) in this setting. METHODSPatients ages 3-21 years were eligible for the current multiinstitutional study. An optional window therapy regimen consisting of 2 cycles of intravenous irinotecan (10 doses of 20 mg/m2 per day separated by 2 days of rest per cycle) was delivered over 6 weeks and was followed by conventionally fractionated RT. The 5-day schedule of temozolomide (200 mg/m2 per day) was initiated 4 weeks after RT and was continued for a total of 6 cycles. The pharmacokinetics of temozolomide and its active metabolite, 5-(3-methyltriazen-1-yl)imidazole-4-carboxamide (MTIC), were analyzed during Cycles 1 and 3. RESULTSThirty-three patients (median age at diagnosis, 6.4 years) were enrolled. Of the 16 patients who received window therapy, 6 had irinotecan treatment discontinued due to clinical progression (n=5) or toxicity (n=1); the remaining 10 experienced disease stabilization after 2 cycles. All patients completed RT (median dose, 55.8 gray). Twenty-nine patients received a combined total of 125 cycles of temozolomide. Grade 3/4 neutropenia and thrombocytopenia occurred in 33% and 29% of all temozolomide cycles, respectively. In approximately one-third of the cycles, dose reduction was required due to myelosuppression. No correlation was demonstrated between temozolomide/MTIC exposure and myelosuppression at the conclusion of Cycle 1. All patients died of disease progression (median survival, 12 months). The estimated 1-year survival rate was 48% (standard error, 8%). CONCLUSIONSThe administration of temozolomide after RT did not alter the poor prognosis associated with newly diagnosed diffuse brainstem glioma in children.
subject
0Administration, Oral–Adverse Effects
1Adolescent–Pharmacokinetics
2Antineoplastic Agents, Alkylating–Therapeutic Use
3Brain Stem Neoplasms–Drug Therapy
4Camptothecin–Pathology
5Child–Radiotherapy
6Child, Preschool–Administration & Dosage
7Dacarbazine–Analogs & Derivatives
8Female–Adverse Effects
9Glioma–Analogs & Derivatives
10Humans–Pharmacokinetics
11Infusions, Intravenous–Therapeutic Use
12Male–Drug Therapy
13Treatment Outcome–Pathology
14Treatment Outcome–Radiotherapy
15Abridged
16Antineoplastic Agents, Alkylating
17Irinotecan
18Dacarbazine
19Camptothecin
20Temozolomide
general
0English
1MEDLINE (ProQuest)
2ProQuest Biological Science Collection
3ProQuest Environmental Science Collection
4ProQuest Natural Science Collection
5ProQuest SciTech Collection
6Agricultural & Environmental Science Database
7Biological Science Database
8Natural Science Collection
9SciTech Premium Collection
10Health Research Premium Collection
11Health Research Premium Collection (Alumni edition)
sourceidproquest
recordidproquest67344570
issn
00008543X
10008-543X
rsrctypearticle
creationdate2005
addtitleCancer
searchscope
01007489
11007527
21007944
310000004
410000006
510000038
610000043
710000050
810000120
910000159
1010000198
1110000200
1210000209
1310000217
1410000234
1510000238
1610000253
1710000260
1810000270
1910000271
2010000302
21proquest
scope
01007489
11007527
21007944
310000004
410000006
510000038
610000043
710000050
810000120
910000159
1010000198
1110000200
1210000209
1310000217
1410000234
1510000238
1610000253
1710000260
1810000270
1910000271
2010000302
21proquest
lsr43
01007489false
11007527false
21007944false
310000004false
410000006false
510000038false
610000043false
710000050false
810000120false
910000159false
1010000198false
1110000200false
1210000209false
1310000217false
1410000234false
1510000238false
1610000253false
1710000260false
1810000270false
1910000271false
2010000302false
contributorBroniscer, Alberto
startdate20050101
enddate20050101
citationpf 133 pt 139 vol 103 issue 1
lsr30VSR-Enriched:[eissn, doi, pqid, galeid]
sort
titleRole of temozolomide after radiotherapy for newly diagnosed diffuse brainstem glioma in children: results of a multiinstitutional study (SJHG-98).
authorBroniscer, Alberto ; Iacono, Lisa ; Chintagumpala, Murali ; Fouladi, Maryam ; Wallace, Dana ; Bowers, Daniel C ; Stewart, Clinton ; Krasin, Matthew J ; Gajjar, Amar
creationdate20050101
lso0120050101
facets
frbrgroupid8477497063354795604
frbrtype5
newrecords20181218
languageeng
creationdate2005
topic
0Administration, Oral–Adverse Effects
1Adolescent–Pharmacokinetics
2Antineoplastic Agents, Alkylating–Therapeutic Use
3Brain Stem Neoplasms–Drug Therapy
4Camptothecin–Pathology
5Child–Radiotherapy
6Child, Preschool–Administration & Dosage
7Dacarbazine–Analogs & Derivatives
8Female–Adverse Effects
9Glioma–Analogs & Derivatives
10Humans–Pharmacokinetics
11Infusions, Intravenous–Therapeutic Use
12Male–Drug Therapy
13Treatment Outcome–Pathology
14Treatment Outcome–Radiotherapy
15Abridged
16Antineoplastic Agents, Alkylating
17Irinotecan
18Dacarbazine
19Camptothecin
20Temozolomide
collection
0MEDLINE (ProQuest)
1ProQuest Biological Science Collection
2ProQuest Environmental Science Collection
3ProQuest Natural Science Collection
4ProQuest SciTech Collection
5Agricultural & Environmental Science Database
6Biological Science Database
7Natural Science Collection
8SciTech Premium Collection
9Health Research Premium Collection
10Health Research Premium Collection (Alumni edition)
prefilterarticles
rsrctypearticles
creatorcontrib
0Broniscer, Alberto
1Iacono, Lisa
2Chintagumpala, Murali
3Fouladi, Maryam
4Wallace, Dana
5Bowers, Daniel C
6Stewart, Clinton
7Krasin, Matthew J
8Gajjar, Amar
jtitleCancer
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
aulast
0Broniscer
1Iacono
2Chintagumpala
3Fouladi
4Wallace
5Bowers
6Stewart
7Krasin
8Gajjar
aufirst
0Alberto
1Lisa
2Murali
3Maryam
4Dana
5Daniel C
6Clinton
7Matthew J
8Amar
au
0Broniscer, Alberto
1Iacono, Lisa
2Chintagumpala, Murali
3Fouladi, Maryam
4Wallace, Dana
5Bowers, Daniel C
6Stewart, Clinton
7Krasin, Matthew J
8Gajjar, Amar
addauBroniscer, Alberto
atitleRole of temozolomide after radiotherapy for newly diagnosed diffuse brainstem glioma in children: results of a multiinstitutional study (SJHG-98).
jtitleCancer
risdate20050101
volume103
issue1
spage133
epage139
pages133-139
issn0008-543X
formatjournal
genrearticle
ristypeJOUR
abstractBACKGROUNDThe role of chemotherapy in the treatment of children with newly diagnosed diffuse brainstem glioma is uncertain. In the current study, the authors tested the efficacy of temozolomide treatment after radiotherapy (RT) in this setting. METHODSPatients ages 3-21 years were eligible for the current multiinstitutional study. An optional window therapy regimen consisting of 2 cycles of intravenous irinotecan (10 doses of 20 mg/m2 per day separated by 2 days of rest per cycle) was delivered over 6 weeks and was followed by conventionally fractionated RT. The 5-day schedule of temozolomide (200 mg/m2 per day) was initiated 4 weeks after RT and was continued for a total of 6 cycles. The pharmacokinetics of temozolomide and its active metabolite, 5-(3-methyltriazen-1-yl)imidazole-4-carboxamide (MTIC), were analyzed during Cycles 1 and 3. RESULTSThirty-three patients (median age at diagnosis, 6.4 years) were enrolled. Of the 16 patients who received window therapy, 6 had irinotecan treatment discontinued due to clinical progression (n=5) or toxicity (n=1); the remaining 10 experienced disease stabilization after 2 cycles. All patients completed RT (median dose, 55.8 gray). Twenty-nine patients received a combined total of 125 cycles of temozolomide. Grade 3/4 neutropenia and thrombocytopenia occurred in 33% and 29% of all temozolomide cycles, respectively. In approximately one-third of the cycles, dose reduction was required due to myelosuppression. No correlation was demonstrated between temozolomide/MTIC exposure and myelosuppression at the conclusion of Cycle 1. All patients died of disease progression (median survival, 12 months). The estimated 1-year survival rate was 48% (standard error, 8%). CONCLUSIONSThe administration of temozolomide after RT did not alter the poor prognosis associated with newly diagnosed diffuse brainstem glioma in children.
urlhttp://search.proquest.com/docview/67344570/
doi10.1002/cncr.20741
eissn10970142
date2005-01-01